Published in Health Business Week, May 25th, 2007
First quarter 2007 revenue increased 47 percent to $212.2 million, versus $144.5 million in the first quarter of 2006. Revenue for company-wide, hospital-based products in the first quarter of 2007 was $140.5 million, which included the acquired anesthetic/analgesic products, a 24 percent increase from the prior year quarter. For the quarter, ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) revenue increased 134 percent to $70.9 million, which included deferred...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.